Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1

Status

Completed 3

Sponsor Class

OTHER 11INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1

Conditions

Zollinger-Ellison Syndrome 1Stomach Ulcer 1Neoplasms 1Neoplasm Metastasis 1Esophagitis, Peptic 1Barrett Esophagus 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Lansoprazole × Clear all
NCT02625259 2018-01-08

A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants

Takeda

Phase 1 Completed
54 enrolled 16 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT00942175 2012-02-03

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

Takeda

Phase 1 Completed
160 enrolled 16 charts
Gastrointestinal

Esophagitis, Peptic, Stomach Ulcer, Zollinger-Ellison Syndrome

NCT00352261 2009-03-26

An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

AstraZeneca

Phase 4 Completed
80 enrolled
Gastrointestinal

Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡